-
Published26/02/2016
-
Deadline07/04/2016
-
Opening of tenders07/04/2016
-
Awarded27/04/2016
-
Today20/08/2026
Utilities
- indicates text translated automatically in your browsing language
Poland-Skąpe: Pharmaceutical products
Supply of medicinal products for the therapeutic treatment of multiple sclerosis by
tasks:
Activity 1 – Interferon beta 1 a (Philosper. and/or injector 30 μg (6mln ju), 0.5 ml x 4)
Activity 2 – Beta 1 b interferon (single injection kit: 1 vial with powder for preparation
solution for injection containing the active substance, 1 solvent ampoule for preparation
solution; vial connector (adapter) and 2 alcohol-soaked knots)
Activity 3 – Glatiramer acetate (20 mg x 28)
Activity 4 – beta 1a 44 mcg- (12 million IU)/0.5 ml solution x 12 amp- syringes=monthly
treatment (provided in ampouple syringes using a Rebiject therapy device for 12 months, i.e. 144
ampouple syringes or interferon beta-1a inj.s.c..132 mcg (36 million IU)/1.5 ml (24 MU)* 4 cartridges=monthly
treatment (provided in multi-dose cartridges using an electronic device for administering the medicine
Rebismart) – treatment for 12 months, i.e. 48 contributions.
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.